Jun Wang

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4715422/publications.pdf

Version: 2024-02-01

113 papers	6,577 citations	66234 42 h-index	76769 74 g-index
131 all docs	131 docs citations	131 times ranked	6065 citing authors

#	Article	IF	Citations
1	Expedited Approach toward the Rational Design of Noncovalent SARS-CoV-2 Main Protease Inhibitors. Journal of Medicinal Chemistry, 2022, 65, 2848-2865.	2.9	102
2	Enterovirus A71 antivirals: Past, present, and future. Acta Pharmaceutica Sinica B, 2022, 12, 1542-1566.	5.7	36
3	Validation and invalidation of SARS-CoV-2 main protease inhibitors using the Flip-GFP and Protease-Glo luciferase assays. Acta Pharmaceutica Sinica B, 2022, 12, 1636-1651.	5.7	55
4	Validation and Invalidation of SARS-CoV-2 Papain-like Protease Inhibitors. ACS Pharmacology and Translational Science, 2022, 5, 102-109.	2.5	30
5	Cytopathic Effect Assay and Plaque Assay to Evaluate in vitro Activity of Antiviral Compounds Against Human Coronaviruses 229E, OC43, and NL63. Bio-protocol, 2022, 12, e4314.	0.2	4
6	Brilacidin, a COVIDâ€19 drug candidate, demonstrates broadâ€spectrum antiviral activity against human coronaviruses OC43, 229E, and NL63 through targeting both the virus and the host cell. Journal of Medical Virology, 2022, 94, 2188-2200.	2.5	20
7	Photothermal card reader assay using the commercial colloidal gold test strip for the rapid quantitative detection of food hazards. Mikrochimica Acta, 2022, 189, 112.	2.5	12
8	The P132H mutation in the main protease of Omicron SARS-CoV-2 decreases thermal stability without compromising catalysis or small-molecule drug inhibition. Cell Research, 2022, 32, 498-500.	5.7	85
9	Drug-Repurposing Screening Identified Tropifexor as a SARS-CoV-2 Papain-like Protease Inhibitor. ACS Infectious Diseases, 2022, 8, 1022-1030.	1.8	13
10	Editorial of Special Column on Antiviral Drug Discovery and Pharmacology. Acta Pharmaceutica Sinica B, 2022, 12, 1540-1541.	5.7	0
11	Invalidation of dieckol and 1,2,3,4,6-pentagalloylglucose (PGG) as SARS-CoV-2 main protease inhibitors and the discovery of PGG as a papain-like protease inhibitor. Medicinal Chemistry Research, 2022, 31, 1147-1153.	1.1	12
12	AG1478 Elicits a Novel Anti-Influenza Function via an EGFR-Independent, GBF1-Dependent Pathway. International Journal of Molecular Sciences, 2022, 23, 5557.	1.8	1
13	Progress and Challenges in Targeting the SARS-CoV-2 Papain-like Protease. Journal of Medicinal Chemistry, 2022, 65, 7561-7580.	2.9	65
14	Stereospecific Effects of Benzimidazolonepiperidine Compounds on T-Type Ca²⁺ Channels and Pain. ACS Chemical Neuroscience, 2022, 13, 2035-2047.	1.7	4
15	Rational design of a deuterium-containing M2-S31N channel blocker UAWJ280 within vivoantiviral efficacy against both oseltamivir sensitive and -resistant influenza A viruses. Emerging Microbes and Infections, 2021, 10, 1832-1848.	3.0	10
16	Dipyridamole, chloroquine, montelukast sodium, candesartan, oxytetracycline, and atazanavir are not SARS-CoV-2 main protease inhibitors. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	48
17	Boceprevir, Calpain Inhibitors II and XII, and GC-376 Have Broad-Spectrum Antiviral Activity against Coronaviruses. ACS Infectious Diseases, 2021, 7, 586-597.	1.8	76
18	High-throughput screening identifies established drugs as SARS-CoV-2 PLpro inhibitors. Protein and Cell, 2021, 12, 877-888.	4.8	95

#	Article	IF	Citations
19	Efficacy of GC-376 against SARS-CoV-2 virus infection in the K18 hACE2 transgenic mouse model. Scientific Reports, 2021, 11, 9609.	1.6	46
20	Rational Design of Hybrid SARS-CoV-2 Main Protease Inhibitors Guided by the Superimposed Cocrystal Structures with the Peptidomimetic Inhibitors GC-376, Telaprevir, and Boceprevir. ACS Pharmacology and Translational Science, 2021, 4, 1408-1421.	2.5	62
21	Discovery of Potent and Broad-Spectrum Pyrazolopyridine-Containing Antivirals against Enteroviruses D68, A71, and Coxsackievirus B3 by Targeting the Viral 2C Protein. Journal of Medicinal Chemistry, 2021, 64, 8755-8774.	2.9	17
22	Discovery of SARS-CoV-2 Papain-like Protease Inhibitors through a Combination of High-Throughput Screening and a FlipGFP-Based Reporter Assay. ACS Central Science, 2021, 7, 1245-1260.	5.3	115
23	Rimantadine Binds to and Inhibits the Influenza A M2 Proton Channel without Enantiomeric Specificity. Biochemistry, 2021, 60, 2471-2482.	1.2	10
24	Discovery of hydrazide-containing oseltamivir analogues as potent inhibitors of influenza A neuraminidase. European Journal of Medicinal Chemistry, 2021, 221, 113567.	2.6	6
25	Thein vitroantiviral activity of lactoferrin against common human coronaviruses and SARS-CoV-2 is mediated by targeting the heparan sulfate co-receptor. Emerging Microbes and Infections, 2021, 10, 317-330.	3.0	126
26	Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19. Nature Communications, 2021, 12, 6055.	5.8	215
27	Influenza AM2 Channel Oligomerization Is Sensitive to Its Chemical Environment. Analytical Chemistry, 2021, 93, 16273-16281.	3.2	12
28	Discovery of Di- and Trihaloacetamides as Covalent SARS-CoV-2 Main Protease Inhibitors with High Target Specificity. Journal of the American Chemical Society, 2021, 143, 20697-20709.	6.6	87
29	Discovery of M2 channel blockers targeting the drug-resistant double mutants M2-S31N/L26I and M2-S31N/V27A from the influenza A viruses. European Journal of Pharmaceutical Sciences, 2020, 141, 105124.	1.9	24
30	Discovery of Influenza Polymerase PAâ€“PB1 Interaction Inhibitors Using an In Vitro Split-Luciferase Complementation-Based Assay. ACS Chemical Biology, 2020, 15, 74-82.	1.6	23
31	X-ray Crystal Structures of the Influenza M2 Proton Channel Drug-Resistant V27A Mutant Bound to a Spiro-Adamantyl Amine Inhibitor Reveal the Mechanism of Adamantane Resistance. Biochemistry, 2020, 59, 627-634.	1.2	23
32	Ebselen, Disulfiram, Carmofur, PX-12, Tideglusib, and Shikonin Are Nonspecific Promiscuous SARS-CoV-2 Main Protease Inhibitors. ACS Pharmacology and Translational Science, 2020, 3, 1265-1277.	2.5	194
33	Pharmacological Characterization of the Mechanism of Action of R523062, a Promising Antiviral for Enterovirus D68. ACS Infectious Diseases, 2020, 6, 2260-2270.	1.8	17
34	Chemical Probes for Blocking of Influenza A M2 Wild-type and S31N Channels. ACS Chemical Biology, 2020, 15, 2331-2337.	1.6	18
35	A modulator of the low-voltage-activated T-type calcium channel that reverses HIV glycoprotein 120-, paclitaxel-, and spinal nerve ligation-induced peripheral neuropathies. Pain, 2020, 161, 2551-2570.	2.0	12
36	Structure and inhibition of the SARS-CoV-2 main protease reveal strategy for developing dual inhibitors against M ^{pro} and cathepsin L. Science Advances, 2020, 6, .	4.7	297

#	Article	IF	Citations
37	Development of broad-spectrum enterovirus antivirals based on quinoline scaffold. Bioorganic Chemistry, 2020, 101, 103981.	2.0	19
38	Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease. Cell Research, 2020, 30, 678-692.	5.7	662
39	Enterovirus D68 Antivirals: Past, Present, and Future. ACS Infectious Diseases, 2020, 6, 1572-1586.	1.8	32
40	Put a cork in it: Plugging the M2 viral ion channel to sink influenza. Antiviral Research, 2020, 178, 104780.	1.9	56
41	Investigation of the Drug Resistance Mechanism of M2-S31N Channel Blockers through Biomolecular Simulations and Viral Passage Experiments. ACS Pharmacology and Translational Science, 2020, 3, 666-675.	2.5	17
42	A Novel Capsid Binding Inhibitor Displays Potent Antiviral Activity against Enterovirus D68. ACS Infectious Diseases, 2019, 5, 1952-1962.	1.8	22
43	Validating Enterovirus D68-2A ^{pro} as an Antiviral Drug Target and the Discovery of Telaprevir as a Potent D68-2A ^{pro} Inhibitor. Journal of Virology, 2019, 93, .	1.5	44
44	X-ray Crystal Structure of the Influenza A M2 Proton Channel S31N Mutant in Two Conformational States: An Open and Shut Case. Journal of the American Chemical Society, 2019, 141, 11481-11488.	6.6	22
45	The L46P Mutant Confers a Novel Allosteric Mechanism of Resistance Toward the Influenza A Virus M2 S31N Proton Channel Blockers. Molecular Pharmacology, 2019, 96, 148-157.	1.0	14
46	Discovery of Quinoline Analogues as Potent Antivirals against Enterovirus D68 (EV-D68). Journal of Medicinal Chemistry, 2019, 62, 4074-4090.	2.9	42
47	Identification of NMS-873, an allosteric and specific p97 inhibitor, as a broad antiviral against both influenza A and B viruses. European Journal of Pharmaceutical Sciences, 2019, 133, 86-94.	1.9	22
48	Focusing on the Influenza Virus Polymerase Complex: Recent Progress in Drug Discovery and Assay Development. Current Medicinal Chemistry, 2019, 26, 2243-2263.	1.2	25
49	Structural basis of adamantane resistance in the influenza A M2 proton channel. Acta Crystallographica Section A: Foundations and Advances, 2019, 75, e140-e140.	0.0	0
50	Profiling the in vitro drug-resistance mechanism of influenza A viruses towards the AM2-S31N proton channel blockers. Antiviral Research, 2018, 153, 10-22.	1.9	19
51	Unraveling the Binding, Proton Blockage, and Inhibition of Influenza M2 WT and S31N by Rimantadine Variants. ACS Medicinal Chemistry Letters, 2018, 9, 198-203.	1.3	16
52	In Vitro Pharmacokinetic Optimizations of AM2-S31N Channel Blockers Led to the Discovery of Slow-Binding Inhibitors with Potent Antiviral Activity against Drug-Resistant Influenza A Viruses. Journal of Medicinal Chemistry, 2018, 61, 1074-1085.	2.9	41
53	Solid-State 2H NMR Investigations of Viral M2 Ion Channel Drugs. Biophysical Journal, 2018, 114, 268a.	0.2	0
54	Exploring Ugi-Azide Four-Component Reaction Products for Broad-Spectrum Influenza Antivirals with a High Genetic Barrier to Drug Resistance. Scientific Reports, 2018, 8, 4653.	1.6	25

#	Article	IF	Citations
55	Functional studies reveal the similarities and differences between AM2 and BM2 proton channels from influenza viruses. Biochimica Et Biophysica Acta - Biomembranes, 2018, 1860, 272-280.	1.4	12
56	Structureâ€“Property Relationship Studies of Influenza A Virus AM2-S31N Proton Channel Blockers. ACS Medicinal Chemistry Letters, 2018, 9, 1111-1116.	1.3	26
57	Symmetric dimeric adamantanes for exploring the structure of two viroporins: influenza virus M2 and hepatitis C virus p7. Drug Design, Development and Therapy, 2018, Volume 12, 1019-1031.	2.0	4
58	Inhibitors of the M2 Proton Channel Engage and Disrupt Transmembrane Networks of Hydrogen-Bonded Waters. Journal of the American Chemical Society, 2018, 140, 15219-15226.	6.6	87
59	Discovery of Highly Potent Pinanamine-Based Inhibitors against Amantadine- and Oseltamivir-Resistant Influenza A Viruses. Journal of Medicinal Chemistry, 2018, 61, 5187-5198.	2.9	22
60	An M2-V27A channel blocker demonstrates potent inÂvitro and inÂvivo antiviral activities against amantadine-sensitive and -resistant influenza A viruses. Antiviral Research, 2017, 140, 45-54.	1.9	44
61	Affinity of Rimantadine Enantiomers against Influenza A/M2 Protein Revisited. ACS Medicinal Chemistry Letters, 2017, 8, 145-150.	1.3	16
62	Expeditious Lead Optimization of Isoxazole-Containing Influenza A Virus M2-S31N Inhibitors Using the Suzukiâ€“Miyaura Cross-Coupling Reaction. Journal of Medicinal Chemistry, 2017, 60, 1580-1590.	2.9	59
63	Design and expeditious synthesis of organosilanes as potent antivirals targeting multidrug-resistant influenza A viruses. European Journal of Medicinal Chemistry, 2017, 135, 70-76.	2.6	27
64	Slow but Steady Wins the Race: Dissimilarities among New Dual Inhibitors of the Wild-Type and the V27A Mutant M2 Channels of Influenza A Virus. Journal of Medicinal Chemistry, 2017, 60, 3727-3738.	2.9	20
65	Protonation equilibria and pore-opening structure of the dual-histidine influenza B virus M2 transmembrane proton channel from solid-state NMR. Journal of Biological Chemistry, 2017, 292, 17876-17884.	1.6	22
66	Discovery of dapivirine, a nonnucleoside HIV-1 reverse transcriptase inhibitor, as a broad-spectrum antiviral against both influenza A and B viruses. Antiviral Research, 2017, 145, 103-113.	1.9	26
67	Influenza A Virus Nucleoprotein: A Highly Conserved Multi-Functional Viral Protein as a Hot Antiviral Drug Target. Current Topics in Medicinal Chemistry, 2017, 17, 2271-2285.	1.0	49
68	Chemical Genomics Approach Leads to the Identification of Hesperadin, an Aurora B Kinase Inhibitor, as a Broad-Spectrum Influenza Antiviral. International Journal of Molecular Sciences, 2017, 18, 1929.	1.8	22
69	Meet Our Regional Editor:. Current Chemical Biology, 2016, 9, 71-72.	0.2	0
70	Computational and Experimental Studies of Lipid-Protein Interactions in Biomemrane Function. Biophysical Journal, 2016, 110, 257a.	0.2	0
71	Discovery of cyclosporine A and its analogs as broad-spectrum anti-influenza drugs with a high inÂvitro genetic barrier of drug resistance. Antiviral Research, 2016, 133, 62-72.	1.9	42
72	Pharmacological Characterization of the Spectrum of Antiviral Activity and Genetic Barrier to Drug Resistance of M2-S31N Channel Blockers. Molecular Pharmacology, 2016, 90, 188-198.	1.0	37

#	Article	IF	Citations
73	Discovery of Potent Antivirals against Amantadine-Resistant Influenza A Viruses by Targeting the M2-S31N Proton Channel. ACS Infectious Diseases, 2016, 2, 726-733.	1.8	32
74	Solid-State NMR Investigation of the Conformation, Proton Conduction, and Hydration of the Influenza B Virus M2 Transmembrane Proton Channel. Journal of the American Chemical Society, 2016, 138, 8143-8155.	6.6	49
75	Discovery of Highly Potent Inhibitors Targeting the Predominant Drug-Resistant S31N Mutant of the Influenza A Virus M2 Proton Channel. Journal of Medicinal Chemistry, 2016, 59, 1207-1216.	2.9	45
76	M2 as a target to combat influenza drug resistance: what does the evidence say?. Future Virology, 2016, 11, 1-4.	0.9	18
77	Recent progress in designing inhibitors that target the drugâ€resistant M2 proton channels from the influenza A viruses. Biopolymers, 2015, 104, 291-309.	1.2	57
78	Inhibitors Targeting the Influenza Virus Hemagglutinin. Current Medicinal Chemistry, 2015, 22, 1361-1382.	1.2	38
79	Flipping in the Pore: Discovery of Dual Inhibitors That Bind in Different Orientations to the Wild-Type versus the Amantadine-Resistant S31N Mutant of the Influenza A Virus M2 Proton Channel. Journal of the American Chemical Society, 2014, 136, 17987-17995.	6.6	78
80	2D IR spectroscopy reveals the role of water in the binding of channel-blocking drugs to the influenza M2 channel. Journal of Chemical Physics, 2014, 140, 235105.	1.2	23
81	De Novo Design of Self-Assembling Foldamers That Inhibit Heparinâ€“Protein Interactions. ACS Chemical Biology, 2014, 9, 967-975.	1.6	39
82	Structure and Inhibition of the M2 Proton Channel from the Influenza a Virus. Biophysical Journal, 2014, 106, 549a.	0.2	0
83	Influenza Virus A M2 Protein Generates Negative Gaussian Membrane Curvature Necessary for Budding and Scission. Journal of the American Chemical Society, 2013, 135, 13710-13719.	6.6	101
84	3-Azatetracyclo[5.2.1.1^{5,8}.0^{1,5}]undecane Derivatives: From Wild-Type Inhibitors of the M2 Ion Channel of Influenza A Virus to Derivatives with Potent Activity against the V27A Mutant. Journal of Medicinal Chemistry, 2013, 56, 9265-9274.	2.9	46
85	Asp44 Stabilizes the Trp41 Gate of the M2 Proton Channel of Influenza A Virus. Structure, 2013, 21, 2033-2041.	1.6	34
86	Structure and inhibition of the drug-resistant S31N mutant of the M2 ion channel of influenza A virus. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 1315-1320.	3.3	204
87	Detection of drugâ€induced conformational change of a transmembrane protein in lipid bilayers using siteâ€directed spin labeling. Protein Science, 2013, 22, 65-73.	3.1	19
88	Discovery of Novel Dual Inhibitors of the Wild-Type and the Most Prevalent Drug-Resistant Mutant, S31N, of the M2 Proton Channel from Influenza A Virus. Journal of Medicinal Chemistry, 2013, 56, 2804-2812.	2.9	88
89	Drug-Induced Conformational and Dynamical Changes of the S31N Mutant of the Influenza M2 Proton Channel Investigated by Solid-State NMR. Journal of the American Chemical Society, 2013, 135, 9885-9897.	6.6	63
90	An Assay Suitable for High Throughput Screening of Anti-Influenza Drugs. PLoS ONE, 2013, 8, e54070.	1.1	5

#	Article	IF	Citations
91	Inhibitors of the Influenza A Virus M2 Proton Channel Discovered Using a High-Throughput Yeast Growth Restoration Assay. PLoS ONE, 2013, 8, e55271.	1.1	48
92	Mapping Water Density to Design New Blockers Against a Viral Proton Channel. Biophysical Journal, 2012, 102, 682a.	0.2	0
93	Photoinduced Electron Transfer and Fluorophore Motion as a Probe of the Conformational Dynamics of Membrane Proteins: Application to the Influenza A M2 Proton Channel. Langmuir, 2011, 27, 3815-3821.	1.6	19
94	Specific Binding of Adamantane Drugs and Direction of Their Polar Amines in the Pore of the Influenza M2 Transmembrane Domain in Lipid Bilayers and Dodecylphosphocholine Micelles Determined by NMR Spectroscopy. Journal of the American Chemical Society, 2011, 133, 4274-4284.	6.6	100
95	Molecular Dynamics Simulation Directed Rational Design of Inhibitors Targeting Drug-Resistant Mutants of Influenza A Virus M2. Journal of the American Chemical Society, 2011, 133, 12834-12841.	6.6	127
96	Exploring Organosilane Amines as Potent Inhibitors and Structural Probes of Influenza A Virus M2 Proton Channel. Journal of the American Chemical Society, 2011, 133, 13844-13847.	6.6	64
97	Exploring the Requirements for the Hydrophobic Scaffold and Polar Amine in Inhibitors of M2 from Influenza A Virus. ACS Medicinal Chemistry Letters, 2011, 2, 307-312.	1.3	51
98	Exploring the Size Limit of Templates for Inhibitors of the M2 Ion Channel of Influenza A Virus. Journal of Medicinal Chemistry, 2011, 54, 2646-2657.	2.9	69
99	Structural and dynamic mechanisms for the function and inhibition of the M2 proton channel from influenza A virus. Current Opinion in Structural Biology, 2011, 21, 68-80.	2.6	117
100	Solid-supported membrane technology for the investigation of the influenza A virus M2 channel activity. Pflugers Archiv European Journal of Physiology, 2010, 459, 593-605.	1.3	12
101	Structure of the amantadine binding site of influenza M2 proton channels in lipid bilayers. Nature, 2010, 463, 689-692.	13.7	590
102	Proton and cation transport activity of the M2 proton channel from influenza A virus. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 15409-15414.	3.3	81
103	Discovery of Spiro-Piperidine Inhibitors and Their Modulation of the Dynamics of the M2 Proton Channel from Influenza A Virus. Journal of the American Chemical Society, 2009, 131, 8066-8076.	6.6	87
104	Design and Pharmacological Characterization of Inhibitors of Amantadine-Resistant Mutants of the M2 Ion Channel of Influenza A Virus. Biochemistry, 2009, 48, 11872-11882.	1.2	98
105	Reversibility of Amantadine Inhibition in the M2 Proton Channel of Influenza A Virus. Biophysical Journal, 2009, 96, 668a.	0.2	0
106	Quantitative Inhibitor Fingerprinting of Metalloproteases Using Small Molecule Microarrays. Journal of the American Chemical Society, 2007, 129, 13110-13117.	6.6	49
107	Inhibitor Fingerprinting of Matrix Metalloproteases Using a Combinatorial Peptide Hydroxamate Library. Journal of the American Chemical Society, 2007, 129, 7848-7858.	6.6	60
108	Protein and small molecule microarrays: powerful tools for high-throughput proteomics. Molecular BioSystems, 2006, 2, 58-68.	2.9	124

#	Article	IF	Citations
109	â€œClickâ€•synthesis of small molecule probes for activity-based fingerprinting of matrix metalloproteases. Chemical Communications, 2006, , 3783-3785.	2.2	37
110	Rapid Assembly of Matrix Metalloprotease Inhibitors Using Click Chemistry. Organic Letters, 2006, 8, 3821-3824.	2.4	50
111	Activity-based high-throughput profiling of metalloprotease inhibitors using small molecule microarrays. Chemical Communications, 2006, , 717.	2.2	25
112	Small Molecule Microarrays: Applications Using Specially Tagged Chemical Libraries. QSAR and Combinatorial Science, 2006, 25, 1009-1019.	1.5	12
113	Recent developments in microarray-based enzyme assays: from functional annotation to substrate/inhibitor fingerprinting. Analytical and Bioanalytical Chemistry, 2006, 386, 416-426.	1.9	52